Waddill William D. sold $897K of PTGX
Waddill William D. sold 9,000 shares of Protagonist Therapeutics, Inc (PTGX) at $99.64 ($0.90M total) on 2026-05-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Provides a dated insider sale (May 29) and the filing date (June 1), including trade price and remaining holdings, but no new operational or clinical information.
Market read
Useful for tracking insider behavior and sentiment, but unlikely to drive a major repricing absent additional fundamental news.
What to watch
Traders may overreact to the headline sale size; the key is whether there are concurrent buys/sales by other insiders or a change in trading patterns around major upcoming catalysts.
Background
The article is an SEC EDGAR Form 4 insider transaction disclosure for Protagonist Therapeutics (PTGX).
Ticker impact
Director Waddill William D. sold 9,000 PTGX shares for ~$896.8K via an open-market transaction under a 10b5-1 plan.
Small, short-lived negative bias possible around disclosure; magnitude likely limited by 10b5-1 context.
The filing provides a concrete ownership-change datapoint (sale size, price, post-sale holdings) but does not indicate new company fundamentals; 10b5-1 reduces interpretive weight.
Market effects
Limited read-across to biotech/clinical-stage peers; this is company-specific insider activity without new clinical/regulatory catalysts.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.
Key entities
- issuerProtagonist Therapeutics, Inc
PTGX, subject of the insider transaction disclosure.
- directorWaddill William D.
Director who sold 9,000 shares under a 10b5-1 plan.
